GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » ROE %

AVANIR Pharmaceuticals (FRA:AV2B) ROE % : -33.54% (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. AVANIR Pharmaceuticals's annualized net income for the quarter that ended in Sep. 2014 was €-43.81 Mil. AVANIR Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Sep. 2014 was €130.63 Mil. Therefore, AVANIR Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2014 was -33.54%.

The historical rank and industry rank for AVANIR Pharmaceuticals's ROE % or its related term are showing as below:

FRA:AV2B' s ROE % Range Over the Past 10 Years
Min: -3615.78   Med: -110.46   Max: 1.02
Current: -63.82

During the past 13 years, AVANIR Pharmaceuticals's highest ROE % was 1.02%. The lowest was -3,615.78%. And the median was -110.46%.

FRA:AV2B's ROE % is not ranked
in the Drug Manufacturers industry.
Industry Median: 4.35 vs FRA:AV2B: -63.82

AVANIR Pharmaceuticals ROE % Historical Data

The historical data trend for AVANIR Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals ROE % Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -116.23 -120.38 -115.25 -266.29 -34.64

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -691.06 -314.24 -276.49 -108.21 -33.54

Competitive Comparison of AVANIR Pharmaceuticals's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVANIR Pharmaceuticals's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's ROE % falls into.



AVANIR Pharmaceuticals ROE % Calculation

AVANIR Pharmaceuticals's annualized ROE % for the fiscal year that ended in Sep. 2014 is calculated as

ROE %=Net Income (A: Sep. 2014 )/( (Total Stockholders Equity (A: Sep. 2013 )+Total Stockholders Equity (A: Sep. 2014 ))/ count )
=-39.138/( (13.816+212.15)/ 2 )
=-39.138/112.983
=-34.64 %

AVANIR Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2014 is calculated as

ROE %=Net Income (Q: Sep. 2014 )/( (Total Stockholders Equity (Q: Jun. 2014 )+Total Stockholders Equity (Q: Sep. 2014 ))/ count )
=-43.808/( (49.102+212.15)/ 2 )
=-43.808/130.626
=-33.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2014) net income data. ROE % is displayed in the 30-year financial page.


AVANIR Pharmaceuticals  (FRA:AV2B) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2014 )
=Net Income/Total Stockholders Equity
=-43.808/130.626
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-43.808 / 101.516)*(101.516 / 162.6975)*(162.6975 / 130.626)
=Net Margin %*Asset Turnover*Equity Multiplier
=-43.15 %*0.624*1.2455
=ROA %*Equity Multiplier
=-26.93 %*1.2455
=-33.54 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2014 )
=Net Income/Total Stockholders Equity
=-43.808/130.626
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-43.808 / -43.796) * (-43.796 / -39.36) * (-39.36 / 101.516) * (101.516 / 162.6975) * (162.6975 / 130.626)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0003 * 1.1127 * -38.77 % * 0.624 * 1.2455
=-33.54 %

Note: The net income data used here is four times the quarterly (Sep. 2014) net income data. The Revenue data used here is four times the quarterly (Sep. 2014) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


AVANIR Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines